Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China: a Retrospective Database-based Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06099028

Enrollment

22500

Registered

2023-10-25

Start date

2021-09-01

Completion date

2023-03-31

Last updated

2024-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.

Interventions

OTHERno intervention

no intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* An index HF diagnosis date in the records * Age ≥ 18 years old at initial diagnosis date * HF patients baseline characteristic record

Design outcomes

Primary

Measure	Time frame	Description
Number of GDMT drugs (classified as RAASi (including ARNI), beta blockers, MRA and SGLT2i)	At baseline and at 1 month, 3 month, 12 month follow-up time point	Numbers of GDMT drugs of HF patients stratified by HF ejection fraction and by HF Center and Non-HF Center
Use rates of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using each GDMT drug，stratified by HF ejection fraction and by HF Center and Non-HF Center

Secondary

Measure	Time frame	Description
The proportion of patients using 4 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using all types of GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients using 2 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using 2 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center
Discontinuation rate of each GDMT drug	at 1 month, 3 month, 12 month follow-up time point	The percentage of patients who discontinued GDMT drugs, stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients with each GDMT drug in the target dose	at 1 month, 3 month, 12 month follow-up time point	The percentage of patients who achieved the target dose of each GDMT drug, stratified by HF ejection fraction and by HF Center and Non-HF Center
The proportion of patients using 3 types of GDMT drugs	At baseline and at 1 month, 3 month, 12 month follow-up time point	The percentage of patients using 3 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026